Sfoglia per AUTORE
GREYSTOKE A
Collezione ASL Asti

  

Items : 2

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. in Journal for immunotherapy of cancer / J Immunother Cancer. 2022 Jan;10(1):e003697. doi: 10.1136/jitc-2021-003697.

2022
ASL Asti

de Bono J; Zucali PA; Lépine L; Abbadessa G; Loumagne L; Chiron M; Wang R; Dong Y; Lee H; Meng R; Perrino M; Pant S; Shen YC; Gutierrez M; Daniele G; Greystoke A; Saleh M; Su WC; Massard C; Iacovelli R; Bauer TM; Italiano A; Tucci M; Lin CC; Carthon BC;

Targeting CD38 and PD-1 with isatuximab (Isa) plus cemiplimab (Cemi) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label, multicenter study in Cancer Research

2021
ASL Asti

Wang R; Loumagne L; De Bono J; Dong Y; Chiron M; Abbadessa G; Lee H; Shen Y-C; Perrino M; Meng R; Gutierrez M; Pant S; Daniele G; Greystoke A; Su W-C; Massard C; Saleh M; Italiano A; Iacovelli R; Carthon B; Bauer TM; Tucci M; Lin C-C; Zucali P;